000			01737na a2200229 4500
003			H12O
005			20180417112805.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCastellano, Daniel _9882 _eOncología Médica
245	0	0	_aFuture perspectives on neuroendocrine tumors _h[artículo]
260			_bCancer and Metastasis Reviews, _c2011
300			_a30(Suppl 1):35-40.
500			_aFormato Vancouver: Castellano D, Salazar R, Raymond E. Future perspectives on neuroendocrine tumors. Cancer Metastasis Rev. 2011;30 Suppl 1:35-40.
501			_aPMID: 21327890
504			_aContiene 45 referencias
520			_aIn the last 30 years the incidence and prevalence of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) has increased substantially. This could be partly due to improvements in diagnostic imaging, which lead to the incidental diagnosis of asymptomatic cases. However, despite these improvements, patients typically experience long delays before they are diagnosed. In this review, we discuss both the limitations and advances in our understanding of the pathogenesis, molecular and cellular biology, diagnosis, classification, staging, and treatment of GEP-NETs in order to identify which factors could be contributing to the delay in diagnosis and timely treatment of these patients. Within this context, the results from the most relevant clinical trials the available targeted therapies for the treatment of GEP-NETs, such as the "RAD001 in Advanced Neuroendocrine Tumors," will be discussed.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/9/pc9893.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c9893 _d9893